ExpreS2ion announces initiation of a Wuhan Coronavirus vaccine program

This is a regulatory release

Hørsholm, Denmark, February 6, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the initiation of a Wuhan Coronavirus (2019-nCoV) vaccine program. ExpreS2ion will produce viral antigens needed for diagnostics and vaccine research, focused on internal vaccine development efforts. The program’s first stage has a timeline of…

ExpreS2ion’s CEO in interview on 2019 and the company’s new way forward with a stronger pipeline focus

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company’s new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS2 platform.

ExpreS2ion is streamlining its market communication with English as primary language

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the company has chosen to streamline its market communication, and will only provide press releases and interim reports in English. ExpreS2ion’s annual report will continue to be published in both Swedish and English. 

ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a…

ExpreS2ion appoints Bent U. Frandsen as Chief Executive Officer

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) today announces that the Company’s Board of Directors has appointed Bent U. Frandsen as the new Chief Executive Officer of ExpreS[2]ion, succeeding Steen Klysner as of today 20 December, 2019. Bent has been with ExpreS[2]ion since March 2016 and has served as the Company’s Chief Business Officer since August 2018.

ExpreS2ion has been awarded SEK 2.7 million for continued development of two malaria vaccine candidates

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) announces that the Company has been awarded SEK 2.7 million as part of the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford, to establish monoclonal Drosophila S2 cell banks for two new malaria vaccine candidates. One targets blood-stage malaria, potentially in combination with the…

ExpreS2ion Biotech Holding AB: Publication of interim report for January – September 2019

This is a regulatory release

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby publishes its interim report for the period January – September 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy

This is a regulatory release

After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.

ExpreS2ion’s joint venture AdaptVac receives Danish InnoBooster grant of 1.2 MSEK for for breast cancer studies in dogs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces today that its joint venture company AdaptVac ApS (“AdaptVac”) has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8 MDKK (approx. 1.2 MSEK). The grant provides further resources for the development of a safe and effective treatment for dogs diagnosed with DER2+ cancer. In addition to…

ExpreS 2 ion secures SEK 8 million in bridge financing to facilitate further growth

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company is increasing its working capital by securing a combination of a bridge loan and a loan facility of up to SEK 8 million in total. This will enable ExpreS2ion to further expand its business activities in line with the growth numbers reported for Q1 and Q2…

New date for publication of interim report 3

This is a regulatory release

Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company will publish its interim report for the period January – September 2019 on November 14th, 2019, instead of the previously scheduled November 21st, 2019. The aim of the advanced publication is to coordinate the release with the Company’s planned participation in a major public investor…

ExpreS2ion receives 1.6 MSEK order in development program for next-generation malaria vaccine

This is a regulatory release

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that it has received a 1.6 MSEK order to perform development work as part of a Wellcome Trust funded malaria vaccine project. The project is led by Jenner Institute at the University of Oxford, and the goal is to create a…

ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion’s licensee Institut Virion\Serion launches the first in vitro diagnostic product based on the ExpreS2-platform

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the Company’s entry on the market for in vitro diagnostic (IVD) applications through its Germany-based licensee Institut Virion\Serion GmbH (“Virion”). Virion is now launching a unique Zika NS1 viral antigen produced in the ExpreS2 platform, and over the next 18 months Virion will increase its offering of products using…

ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new…

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

This is a regulatory release

ExpreS2ion Biotech Holding AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding Certified Adviser services. SKMG will be appointed as Certified Adviser on the 1st of July 2019. Until the 1st of July 2019, Sedermera Fondkommission will continue to act as Certified Adviser for the Company.

ExpreS2ion co-author of article demonstrating that human antibodies from RH5 vaccine block binding to blood cells

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that a scientific article, documenting that human antibodies against the RH5 protein can stop the malaria parasite from entering human blood cells, has been published in the highly renowned journal Cell. The article is based on a clinical study conducted by researchers at the University of Oxford together with…

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

This is a regulatory release

This is an unofficial translation of a report from the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, on May 23, 2019, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was…

ExpreS2ion Biotech Holding AB: Publication of interim financial report for January – March 2019

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – March 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2018

This is a regulatory release

The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2018. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).

ExpreS2ion announces the publication of a proof of concept in animals for a new potential breakthrough malaria vaccine

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the publication of a scientific article in Cellular Microbiology providing the first proof of concept in an animal model for a next generation malaria vaccine that is targeting a recently discovered molecular ’key’ that the deadly malaria parasite uses to enter human blood cells.

Correction: Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…

ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).

Report from Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

On the 19th of March 2019, an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB was held. Below is a summary of the decisions that were taken. All decisions were taken with required majority.

ExpreS2ion will attend and present its ExpreS2 technology platform at several key events in March and April

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, In Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA. 

Notice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is a regulatory release

The shareholders of ExpreS2ion Biotech Holding AB, 559033-3729, are hereby invited to attend an Extraordinary General Meeting on Tuesday, March 19, 2019, at 10.00 at c/o Mazars SET, Terminalgatan 1, in Helsingborg.

ExpreS2ion conducts a directed share issue to accelerate the development of the company

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company is conducting a directed share issue to a number of existing shareholders and strategic investors of initially approx. SEK 8 million, with attached consideration-free warrants, which in later stages can provide the Company with a further approx. SEK 9.6 million. The directed share issue is…

ExpreS2ion Biotech Holding AB: Publication of financial report for January – December 2018

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – December 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion’s joint venture AdaptVac receives SEK 3.6 million grant for vaccine to reduce antibiotic usage in pigs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry.

ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.

ExpreS2ion’s joint venture AdaptVac receives grants for two new projects: cardiovascular disease and breast cancer in dogs

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical…

ExpreS2ion’s patent and research partner publishes malaria vaccine breakthrough in Nature

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough…

ExpreS2ion Biotech Holding AB: Publication of financial report for January – September 2018

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – September 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford

This is a regulatory release

Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown…

ExpreS2ion will present its ExpreS2 technology platform at several key events in October and November

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will participate at several key events in October and November, including World Vaccine Congress, October 29-31, 2018, in Lisbon, Portugal, and Sedermeradagen, November 7, 2018, in Stockholm, Sweden. 

ExpreS2ion announces upcoming presentation of Phase I/IIa malaria vaccine trial results by Jenner Institute

This is a regulatory release

Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st…

ExpreS2ion’s proprietary platform used for successful production of another transmission blocking malaria vaccine candidate

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a recently published scientific article in Nature Communications on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS2 platform is an excellent tool for producing transmission blocking malaria vaccines. This is a promising class of next generation vaccines,…

ExpreS2ion’s joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step…

ExpreS2ion’s own Zika virus antigen products included in agreement with U.S.-based Integrated BioTherapeutics

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that it has amended its Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) to include own ExpreS2-based products, initially a number of Zika virus antigens.

ExpreS2ion Biotech Holding AB: Publication of financial report for January – June 2018

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – June 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion’s platform (ExpreS2) featured in npj Vaccines article on malaria vaccine candidate production

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a scientific article on the production of a malaria vaccine candidate using the Company’s ExpreS2 platform was published today in the journal npj Vaccines, a part of Nature Partner Journals Series. The article “Production, quality control, stability, and potency of cGMP-produced Plasmodium…

ExpreS2ion appoints CBO and IR partner

ExpreS2ion Biotechnologies ApS (“ExpreS2ion") has appointed Bent U. Frandsen, currently VP of Business Development, as Chief Business Officer (CBO). He will manage a proactive effort to substantially increase the customer base in the Company’s vaccine development and production services segment. Furthermore, ExpreS2ion appoints Honeybadger as non-exclusive IR partner on the Swedish market.

ExpreS2ion will present its malaria and breast cancer vaccine research at two scientific events in June

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will hold presentations at an annual meeting hosted by the World Biopharm Forum in Oxford, UK, June 20-22 and at the Vaccine Technology VII Meeting in Mont Tremblant, Quebec, Canada, June 17-22.

ExpreS2ion and GenIbet sign collaboration agreement for vaccine development and GMP production

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has signed a collaboration agreement regarding vaccine development and GMP (Good Manufacturing Practice) manufacturing with its Portuguese partner GenIbet Biopharmaceuticals, S.A. (“GenIbet”). The agreement strengthens ExpreS2ion’s position as a full-service provider from discovery up to early clinical development.

Report from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting

This is a regulatory release

Today, May 24th, 2018, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was held. A summary of the decisions that were made follows below. All decisions were taken with required majority.

ExpreS2ion’s core platform patent allowed in Canada

This is a regulatory release

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.

ExpreS2ion Biotech Holding AB: Publication of financial report for January – March 2018

This is a regulatory release

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report the period of January – March 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

ExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2017

This is a regulatory release

The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2017. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).

ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product

This is a regulatory release

ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development…